版本:
中国

BRIEF-Clovis Oncology says topline data from Ariel3 trial of rucaparib achieved primary endpoint

June 19 Clovis Oncology Inc:

* Clovis Oncology - announced topline data from the confirmatory phase 3 ariel3 trial of rucaparib

* Clovis Oncology - ariel3 trial achieved primary endpoint of improved progression-free survival by investigator review in each of 3 populations studied

* Clovis Oncology - PFS was improved in rucaparib group compared with placebo by blinded independent central review (BICR) a key secondary endpoint

* Clovis Oncology - company plans to submit a supplemental NDA within the next four months Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐